Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

Bibliographic Details
Main Authors:	Ayalew Tefferi, Animesh Pardanani, Kebede H. Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-03-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-024-01028-4

Internet